Skip to content

Effects of Combined 40 Hz Audio-visual Stimulation and Cognitive Games on Alzheimer's Disease

Development of a Sensory Entrainment-Integrated Cognitive Game Kit to Improve Cognitive Functions in Alzheimer's Disease

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06595511
Enrollment
30
Registered
2024-09-19
Start date
2022-10-01
Completion date
2025-04-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

40 Hz Stimulation, Alzheimer's Disease, EEG Brain Oscillations

Brief summary

In addition to ongoing drug treatments for Alzheimer Disease (AD), protective approaches that can halt the progression of the disease are of particular importance. This project aims to develop a digital application that can monitor cognitive impairment, using EEG findings proven effective at the clinical level in Alzheimer and various types of dementia, including sensory entrainment and digital cognitive games. To this end, a collaboration between Istanbul Medipol University and Güven Future Health Technologies Inc. will develop a device featuring audio-visual sensory entrainment and digital cognitive games. This device will be made available to Alzheimer patients, and the differences between patients who use the application for three months, patients who do not use the application, and healthy controls will be evaluated through neurological examinations, neuropsychological tests, and EEG recordings indicating cognitive functions by the neurologist, project coordinator, and bursars. Monthly assessments, including EEG recordings, will also continue at home, and an application will be created to evaluate changes in cognitive functions through EEG data. By the end of the project, an application that includes sensory entrainment and digital cognitive games, proven effective at the clinical level using EEG findings for Alzheimer dementia patients, will be developed. Additionally, a health kit capable of temporal monitoring of cognitive function changes through EEG data will have been developed.

Detailed description

This study aims to recruit early and middle-stage Alzheimer patients aged between 60 and 75, along with age and gender-matched healthy older adults. Two different Alzheimer groups will be created: one group will utilize a 40 Hz sensory entrainment-integrated cognitive game kit at home, while the other group will not receive any treatment. The treatment group will comprise 10 Alzheimer patients who will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for 1 hour a day, at least five days a week, for three months. Comprehensive neuropsychological assessments and electroencephalography (EEG) recordings will be conducted in the laboratory on the first day, followed by mobile EEG recordings at home at the end of the first and second months. After three months of using the sensory entrainment/cognitive game kit, the participants will again undergo neuropsychological assessment and EEG recording in the laboratory. The second Alzheimer group (n=10) will not be administered any treatment and will undergo the same assessment protocol as the treatment group. Furthermore, in addition to these two groups, a healthy older adult group (n=10) will also be included in the study, with assessments scheduled only on the first day and at the end of the third month.

Interventions

DEVICESensory Entrainment-Integrated Cognitive Game Kit

Active comparator group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, at least five days a week, for three months.

Sponsors

The Scientific and Technological Research Council of Turkey
CollaboratorOTHER
Guven Health Group
CollaboratorOTHER
Istanbul Medipol University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 86 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion and

Exclusion criteria

for Alzheimer Patients: Inclusion Criteria: * Diagnosed with AD according to DSM-IV and NINCDS-ADRDA criteria, * Impaired activities of daily living, * Having a CDR score of 1-2 and an SMMT score of 15-26, * Stable use of psychoactive medications, including acetylcholinesterase inhibitors or other medications that enhance cognitive functions, * Individuals aged 60-86 with at least 5 years of education.

Design outcomes

Primary

MeasureTime frameDescription
EEG recordingAt baseline and month 3EEG will be recorded under these conditions: * Spontaneous EEG (8 minutes eyes open, 8 minutes eyes closed) * Visual oddball * Auditory oddball * 40 Hz flicker stimulation EEG recording (8 minutes eyes open, 8 minutes eyes closed)

Secondary

MeasureTime frameDescription
Standardized Mini Mental State Examination (SMMSE)At baseline and month 3For the comprehensive cognitive status
Verbal memory processes test (Öktem-SBST) and Wechsler Visual Production SubtestAt baseline and month 3For the assessment of memory functions
WMS-R Digit Span TestAt baseline and month 3For the assessment of attention
Boston Naming TestAt baseline and month 3For the assessment of language functions
Benton Line Orientation Test and Benton Face Recognition TestAt baseline and month 3For the assessment of visuospatial functions
Stroop Test, Clock Drawing Test, Verbal Fluency Tests (categorical and phonemic) and Trail Making TestAt baseline and month 3For the assessments of executive function

Other

MeasureTime frameDescription
Mobile EEG recording at homemonth 1 and 2EEG will be recorded under these conditions: * Spontaneous EEG (8 minutes eyes open, 8 minutes eyes closed) * 40 Hz flicker stimulation EEG recording (8 minutes eyes open, 8 minutes eyes closed) Delta, theta, alpha, beta, gamma power spectrum and phase locking indexes will be examined.

Countries

Turkey (Türkiye)

Contacts

Primary ContactBahar Güntekin, PhD
bguntekin@medipol.edu.tr+90 5326031560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026